Other News

Implicity Inc. Signs U.S. Distribution Agreement with MicroPort CRM USA

Deal allows global cardiac device manufacturer to enhance its offerings in the U.S. with Implicity’s cloud-based and AI-driven universal cardiac remote monitoring platform to provide high-value services to healthcare providers CAMBRIDGE, Mass., May 27, 2021 /PRNewswire/ — Implicity, a leader in remote patient monitoring software and cardiac data management solutions, announced a distribution […]

Medtronic Reports Fourth Quarter and Fiscal Year 2021 Financial Results; Announces 9% Dividend Increase

– Q4 Revenue of $8.2 Billion Increased 37% Reported and 32% Organic– Q4 GAAP Diluted EPS of $1.00; Q4 Non-GAAP Diluted EPS of $1.50– Quarterly Dividend Increased to $0.63, Annual $2.52 from Prior $2.32; 44th Consecutive Year of Dividend Increases– Company Issues FY22 Guidance– Guidance Reflects FY22 Revenue Growth above […]

FDA Grants Micro Interventional Devices, Inc. Breakthrough Device Designation for the MIA™-T Percutaneous Tricuspid Annuloplasty System

NEWTOWN, Pa., May 27, 2021 /PRNewswire/ — Micro Interventional Devices (MID) has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its MIA™-T Percutaneous Tricuspid Annuloplasty System.  The MIA-T system treats moderate-severe tricuspid regurgitation (TR) via a 12F catheter-based system. MID develops proprietary Transcatheter Cardiac Repair (TCR) technologies addressing unmet […]

SINOMED announces the HT Supreme DES has similar performance as the market-leader across the spectrum of lesion complexity

TIANJIN, China, May 27, 2021 /PRNewswire/ — SINOMED, a leading international medical device company, today announced results from the HT Supreme™ Healing-Targeted Drug-Eluting Stent (DES), in complex patients compared to the Xience or Promus family of DES.  One-year results were presented at last week’s 2021 EuroPCR annual congress showing that the two […]

Acutus Medical Receives FDA Approval to Initiate US Atrial Fibrillation IDE Trial with the AcQBlate® FORCE Sensing Ablation System

CARLSBAD, Calif., May 27, 2021 (GLOBE NEWSWIRE) — Acutus Medical (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced FDA approval for the company to initiate its Atrial Fibrillation (“AF”) Investigational Device Exemption (IDE) clinical trial for the AcQBlate Force […]

Sequana Medical announces results of Annual and Extraordinary General Meetings of Shareholders

Ghent, BELGIUM – 27 May 2021 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical”), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, today announces that all proposed resolutions submitted to the Annual and Extraordinary General Meeting of Shareholders were approved at the meetings held […]

FEops HEARTGuide Combines Digital Twins and AI to Revolutionize Structural Heart Planning

GENT, Belgium–(BUSINESS WIRE)–FEops strengthens its position as the cloud-based digital health player in the structural heart space by introducing Artificial Intelligence into its CE marked FEops HEARTguide platform. FEops HEARTguide is a one-in-its-kind procedure planning platform for structural heart interventions that provides physicians with unique insights to evaluate device sizing and positioning pre-operatively. The […]

Scientia Raises $50M Growth Equity Investment from Vivo Capital

SALT LAKE CITY–(BUSINESS WIRE)–Scientia Vascular (“Scientia” or the “Company”), a rapidly growing commercial company focused on helping save patients’ lives with a suite of interventional medical devices, has raised $50M of growth equity financing from Vivo Capital, a Palo Alto, CA-headquartered global healthcare investment firm. The financing will be used […]

Varian Receives FDA “Breakthrough Device Designation” for its Cardiac Radioablation (CRA) System for Treatment of Refractory Ventricular Tachycardia (VT)

– Varian’s CRA system has been designated a “breakthrough device” by the FDA because of its potential to offer a more effective treatment for select patients with refractory VT. – Technology being developed will be assessed in clinical studies as a noninvasive treatment for select patients with refractory VT. PALO […]